




RealRate

PHARMACEUTICAL 2017

Theravance Biopharma Inc.
Rank 88 of 313

Theravance
Biopharma 
Medicines That Make a Difference®



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai



PHARMACEUTICAL 2017

Theravance Biopharma Inc. Rank 88 of 313



The relative strengths and weaknesses of Theravance Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Theravance Biopharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 147% points. The greatest weakness of Theravance Biopharma Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 32% points.

The company's Economic Capital Ratio, given in the ranking table, is -36%, being 380% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	528,503
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	49,268
Liabilities, Non-Current	0
Other Assets	102,291
Other Compr. Net Income	-183
Other Expenses	14,408
Other Liabilities	0
Other Net Income	1,312
Property and Equipment	8,460
Research and Development	141,712
Revenues	48,648
Selling, General and Administrative Expense	84,509

Output Variable	Value in 1000 USD
Assets	639,254
Liabilities	49,268
Expenses	240,629
Stockholders Equity	589,986
Net Income	-190,669
Comprehensive Net Income	-190,760
Economic Capital Ratio	-36%

